Breast oncology Clinical Trials in Nashville, TN
As of June 2026, 80 paid clinical trials are recruiting for Breast oncology in Nashville, Tennessee. Breast oncology research tests new hormone therapies, HER2-targeted agents, PARP inhibitors, antibody-drug conjugates, and immunotherapy combinations across early-stage and metastatic disease. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
80 clinical trials for Breast oncology
·Clear filters·↓ Download CSVStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of LY4175408 in Participants With Advanced Cancer
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
E-Mindfulness Approaches for Living After Breast Cancer
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Study of DM001 in Patients With Advanced Solid Tumors
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A Phase 1/1b Study of IAM1363 in HER2 Cancers
About research studies in Nashville
Nashville has approximately 1,421 recruiting research studies across a wide range of therapeutic areas. Tennessee is home to Vanderbilt University Medical Center and St. Jude Children's Research Hospital — world leaders in pediatric oncology and personalized medicine.
Top Research Study Locations in Nashville
Researchers run research studies in Nashville, TN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Vanderbilt University Medical Center | Parkinson Disease, Colorectal Cancer, Obesity | 379 |
| SCRI Oncology Partners | Breast Cancer, Advanced Solid Tumor, Colorectal Cancer | 123 |
| Vanderbilt University/Ingram Cancer Center | Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 95 |
| Sarah Cannon Research Institute | Advanced Solid Tumor, Colorectal Cancer, Advanced Solid Tumors | 65 |
| Vanderbilt University | Breast Cancer, Cardiac Failure, Graft Rejection | 58 |
| Tennessee Oncology | Breast Cancer, Multiple Myeloma, Carcinoma, Non-Small-Cell Lung | 54 |
| Vanderbilt-Ingram Cancer Center | Breast Cancer, Colorectal Cancer, Endometrial Cancer | 41 |
| The Children's Hospital at TriStar Centennial | Malignant Solid Neoplasm, B Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 27 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Hypertension, Acute Kidney Injury, Acute Myeloid Leukemia | 17 |
| Tennessee Oncology, PLLC | Advanced Solid Tumor, Breast Cancer, Metastatic Breast Cancer | 15 |
| Vanderbilt Breast Center at One Hundred Oaks | Metastatic Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8, Advanced Malignant Solid Neoplasm | 15 |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Cardiovascular Disease, Acute Kidney Injury (AKI), Aging | 12 |
| TriStar Centennial Medical Center | Acute Lower Limb Arterial Occlusion, Acute Myeloid Leukemia (AML), Aortic Stenosis | 12 |
| Tennessee Retina, PC | Geographic Atrophy, Neovascular Age-Related Macular Degeneration (nAMD), AMD | 9 |
| Ascension Saint Thomas | Coronary Artery Disease, Mitral Regurgitation, Atrial Fibrillation, Postoperative | 8 |
| GSK Investigational Site | Neoplasms, Hypereosinophilic Syndrome, Multiple Myeloma | 8 |
| Vanderbilt Eye Institute | Macular Edema Secondary to Inflammation, Age-related Macular Degeneration (AMD), Diabetic Retinopathy | 8 |
| Vanderbilt Ingram Cancer Center | AL Amyloidosis, Adamantinomatous Craniopharyngioma, Advanced Solid Tumors | 8 |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Metastatic Solid Tumor, Ovarian Cancer, Advanced NRAS-Mutant Melanoma | 7 |
| Sarah Cannon Research Institute - Pharmacy | Gastroesophageal Junction Adenocarcinoma, Breast Neoplasms, Stomach Neoplasms | 7 |
| Urology Associates, P.C. | NMIBC, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Cancer of the Prostate | 7 |
| Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Autonomic Failure, Multiple System Atrophy, Pure Autonomic Failure | 6 |
| Centennial Medical Center | Cardiovascular Diseases, Coronary Artery Disease, Heart Failure | 6 |
| Henry-Joyce Cancer Clinic | Colorectal Neoplasms, Multiple Myeloma, Breast Cancer | 6 |
| Meharry Medical College | ARDS, Cardiovascular Diseases, Cognitive Impairment, Mild | 6 |
Active & Upcoming Studies in Nashville (2026)
Recruiting trials in Nashville grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (591 active studies)
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · Phase 2 · National Cancer Institute (NCI)
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · Phase 1 · Eli Lilly and Company
Cardiovascular (85 active studies)
- Improving Veteran Referral to Cardiac Rehabilitation · VA Office of Research and Development
- Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) · Stanford University
Neurology & pain (66 active studies)
- Individual vs Co-Treatment in Acute Stroke Rehabilitation and Evaluation · Vanderbilt University Medical Center
- Cholinergic Deep Brain Stimulation for Alzheimer's Disease · Vanderbilt University Medical Center
Diabetes & metabolic (52 active studies)
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · Novo Nordisk A/S
- Transition to Ambulatory Bariatric Surgery (TABS) Trial · Vanderbilt University Medical Center
Eye & vision (21 active studies)
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
- Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy · Phase 4 · Toyos Clinic
Mental health & behavior (13 active studies)
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · Vanderbilt University Medical Center
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Vaccines (11 active studies)
- Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · Vanderbilt University Medical Center
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) · Phase 2 · Vanderbilt University Medical Center
HIV / STI (10 active studies)
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Pediatric (10 active studies)
- Neonatal Platelet Transfusion Threshold Trial · NICHD Neonatal Research Network
- Project PAIR: Parent-implemented Articulation Intervention With Recast · Vanderbilt University
Common conditions studied in Nashville
- Breast Cancer (45 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (33 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colorectal Cancer (29 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Ovarian Cancer (26 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumors (25 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Multiple Myeloma (23 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Tennessee are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Tennessee research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Nashville. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Nashville
Hipa.ai aggregates every recruiting study in Nashville from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,421 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (45), Advanced Solid Tumor (33), Colorectal Cancer (29), Ovarian Cancer (26), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (591), Cardiovascular (85), Neurology & pain (66). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.